Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49)
Monoclonal antibodies that target CD20 expressing B cells represent an important new treatment option for patients with multiple sclerosis (MS). This therapy may be associated with an increased risk of adverse effects which are reviewed in this study. The generally favorable safety profile of anti-...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Iran University of Medical Sciences
2023-01-01
|
| Serija: | Neurology Letters |
| Teme: | |
| Online pristup: | https://www.neurologyletters.com/article_184690_d41d8cd98f00b204e9800998ecf8427e.pdf |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|